On the future of HLA

Tissue Antigens

Volumn 78, Issue 4, 2011, Pages 229-240

  Thorsby, E ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

Anthropology; Autoimmune diseases; Graft versus leukemia; Hematopoietic stem cell transplantation; Human leucocyte antigens; Organ transplantation; Pharmacogenomics; Vaccination

Indexed keywords

ABACAVIR; ALLOANTIGEN; ALLOPURINOL; AUTOANTIGEN; CARBAMAZEPINE; DNA VACCINE; EPITOPE; GLIADIN; GLUTEN; HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; HLA DR4 ANTIGEN; MITOCHONDRIAL DNA; PLASMID DNA; TUMOR ANTIGEN;

ANTIBODY DETECTION; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNE DISEASE; CELIAC DISEASE; DRUG HYPERSENSITIVITY; EPILEPSY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GOUT; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERURICEMIA; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENETICS; IMMUNOSUPPRESSIVE TREATMENT; MELANOMA; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; ORGAN DONOR; ORGAN TRANSPLANTATION; OSTEOPOROSIS; PATHOGENESIS; PHARMACOGENOMICS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; STEVENS JOHNSON SYNDROME; T CELL DEPLETION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TOXIC EPIDERMAL NECROLYSIS; UNSPECIFIED SIDE EFFECT; UPREGULATION; VACCINATION;

AUTOIMMUNE DISEASES; GENETIC PREDISPOSITION TO DISEASE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA ANTIGENS; HUMANS;

EID: 80052993252     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2011.01770.x     Document Type: Article

References (72)

1. Thorsby E. A short history of HLA. Tissue Antigens 2009: 74: 101-16.
2. Vartdal F, Gaudernack G, Funderud S et al. HLA class I and II typing using cells positively selected from blood by immunomagnetic isolation in a fast and reliable technique. Tissue Antigens 1986: 28: 301-12.
3. Leivestad T, Sødal G, Bratlie A et al. Role of HLA matching in cadaveric renal transplantation: influence of improved serological HLA-DR typing. Transpl Proc 1993: 25: 220-1.
4. Jakobsen BK, Ryder LP, Ladefoged J et al. Strong impact of HLA-DR-matching on graft survival in 413 consecutive cadaver kidney transplants performed in Copenhagen over an eight-year period. Transpl Proc 1995: 27: 3452-7.
5. Connolly JK, Dyer PA, Matin S, Parrott NR, Pearson RC, Johnson RWG. Importance of minimizing HLA-DR mismatch and cold preservation time in cadaveric renal transplantation. Transplantation 1996: 61: 709-14.
6. Reisæther A, Leivestad T, Vartdal F et al. A strong impact of matching for a limited number of HLA-DR antigens on graft survival and rejection episodes: a single center study of first cadaveric kidneys to non-sensitized patients. Transplantation 1998: 66: 523-8.
7. Opelz G, Døhler B. Association of mismatches for HLA-DR with incidence of posttransplant hip fracture in kidney transplant recipients. Transplantation 2011: 91: 65-9.
8. Opelz G, Døhler B. Impact of HLA mismatching on incidence of post-transplant non-Hodgkin lymphoma after kidney transplantation. Transplantation 2010: 89: 567-72.
9. Newell KA, Asare A, Kirk AD et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 2010: 120: 1836-47.
10. Kawai T, Cosimi AB, Spitzer TR et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008: 358: 353-61.
11. Bluestone JA, Auchincloss H, Nepom GT, Rotrosen D, St.Clair EW, Turka LA. The immune tolerance network at 10 years: tolerance research at the bedside. Nat Rev Immunol 2010: 10: 797-803.
12. Terasaki PI, Cai J. Human leukocyte antigen antibodies and chronic rejection; from association to causation. Transplantation 2008: 86: 377-83.
13. Duquesnoy RJ. Antibody-reactive epitope determination with HLAMatchmaker and its clinical applications. Tissue Antigens 2011: 77: 525-34.
14. Meier-Kriesche HU, Scornik JC, Susskind B, Rehman S, Schold JD. A lifetime versus a graft life approach redefines the importance of HLA matching in kidney transplant patients. Transplantation 2009: 88: 23-9.
15. Gras S, Kjer-Nielsen L, Chen Z, Rossjohn J, McCluskey J. The structural bases of direct T-cell allorecognition: implications for T-cell mediated transplant rejection. Immunol and Cell Biol 2011: 89: 388-95.
16. D'Orsogna LJA, Roelen DL, Doxiadis IIN, Claas FHJ. Alloreactivity from human viral specific memory T-cells. Transpl Immunol 2010: 23: 149-55.
17. Susal C, Morath C. Current approaches to the management of highly sensitized kidney transplant patients. Tissue Antigens 2011: 77: 177-86.
18. Claas FHJ, Rahmel A, Doxiadis IIN. Enhanced kidney allocation to highly sensitized patients by the acceptable mismatch program. Transplantation 2009: 88: 447-52.
19. Opelz G, Claas FHJ, eds. Special issue on clinical relevance of HLA antibodies in transplantation. Hum Immunol 2009: 70: 561-658.
20. Van den Berg-Loonen EM, Billen EV, Voorter CE et al. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation 2008: 85: 1086-90.
21. Barrett J, Gluckman E, Handgretinger R, Madrigal A. Point-counterpoint: haploidentical family donors versus cord blood transplantation. Biol Blood Marrow Transplant 2011: 17 (Suppl 1): s89-s93.
22. Petersdorf EW. HLA matching in allogeneic stem cell transplantation. Curr Op Hemat 2004: 11: 386-91.
23. Lee SJ, Klein J, Haagenson M et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007: 110: 4576-83.
24. Petersdorf EW, Hansen JA. New advances in hematopoietic cell transplantation. Curr Opin Hematol 2008: 15: 549-54.
25. Shaw BE, Arguello R, Garcia-Sepulveda CA, Madrigal JA. The impact of HLA genotyping on survival following unrelated donor haematopoietic stem cell transplantation. Br J Haematol 2010: 150: 251-8.
26. Crocchiolo R, Zino E, Vago L et al. Nonpermissive HLA-DP disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation. Blood 2009: 114: 1437-44.
27. + T cells responding to nonpermissive than to permissive HLA-DPB1 T-cell epitope disparities [letter]. Blood 2010: 116: 1991-2.
28. Van Rood JJ, Loberiza FR, Zhang MJ et al. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. Blood 2002: 99: 1572-7.
29. Van Rood JJ, Stevens CE, Smits J, Carrier C, Carpenter C, Scaradavou A. Reexposure of cord blood to noninherited maternal HLA antigens improves transplant outcome in hematological malignancies. Proc Nat Acad Sci U S A 2009: 106: 19952-7.
30. Heemskerk MBA, Roelen DL, Dankers MKA et al. Allogeneic MHC molecules with numerous sequence differences do not elicit a CTL response. Hum Immunol 2005: 66: 969-76.
31. Heemskerk MBA, Cornelissen JJ, Roelen DL et al. Highly diverged MHC class I mismatches are acceptable for hematopoietic stem cell transplantation. Bone Marrow Transpl 2007: 40: 193-200.
32. Erlich RL, Jia X, Anderson S et al. Next-generation sequencing for HLA typing of class I loci. BMC Genomics 2011: 12: 42.
33. Holcomb CL, Hoglund B, Anderson MW et al. A multi-site study using high-resolution HLA genotyping by next generation sequencing. Tissue Antigens 2011: 77: 206-17.
34. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990: 75: 555-62.
35. Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002: 295: 2097-100.
36. Ruggeri L, Mancusi A, Capanni M et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007: 110: 433-40.
37. Willemze R, Rodrigues CA, Labopin M et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia 2009: 23: 492-500.
38. O'Reilly RJ, Dao T, Koehne G, Scheinberg D, Doubrovina E. Adoptive transfer of unselected or leukaemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation. Sem Immunol 2010: 22: 162-72.
39. Stronen E, Abrahamsen IW, Gaudernack G et al. Dendritic cells engineered to express defined allo-HLA peptide complexes induce antigen-specific cytotoxic T cells effectively killing tumor cells. Scand J Immunol 2009: 69: 319-28.
40. Abrahamsen IW, Stronen E, Walchli S et al. Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif. Leukemia 2010: 24: 1901-9.
41. Abrahamsen IW, Kjellevoll S, Greve-Isdahl M et al. T cells raised against allogeneic HLA-A2/CD20 kill primary follicular lymphoma and acute lymphoblastic leukemia cells. Int J Cancer 2011. May 31.doi:10.1002/ijc.29209.
42. Brewerton DA, Caffrey M, Hart FD, James DCO, Nicholls A, Sturrock RD. Ankylosing spondylitis and HL-A 27. Lancet 1973: 1: 904-7.
43. Schlosstein L, Terasaki PI, Bluestone R et al. High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med 1973: 288: 704-8.
44. Thorsby E. Invited anniversary review: HLA associated diseases. Hum Immunol 1977: 53: 1-11.
45. Todd JA, Walker NM, Cooper JD et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genetics 2007: 39: 857-64.
46. Rai E, Wakeland EK. Genetic predisposition to autoimmunity - what have we learned? Sem Immunol 2011: 23: 67-83.
47. Lie BA, Todd JA, Pociot E et al. The predisposition to type 1 diabetes linked to the human leukocyte antigen complex includes at least one non-class II gene. Am J Hum Genet 1999: 64: 793-800.
48. Aly TA, Bascchal EE, Jahromi MM et al. Analysis of single nucleotide polymorphisms identifies major type 1A diabetes locus telomeric of the major histocompatibility complex. Diabetes 2008: 57: 770-6.
49. Viken MK, Blomhoff A, Olsson M et al. Reproducible association with type 1 diabetes in the extended class I region of the major histocompatibility complex. Genes Immun 2009: 10: 323-33.
50. International MHC and Autoimmunity Genetics Network (IMAGEN). Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proc Nat Acad Sci U S A 2009: 106: 18680-5.
51. Todd JA. Etiology of type 1 diabetes. Immunity 2010: 32: 457-67.
52. The International Multiple Sclerosis Genetics Consortium & the Wellcome Trust Case Control Consortium. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011: 476: 214-9.
53. Sollid LM. Coeliac disease: dissecting a complex inflammatory disorder. Nat Rev Immunol 2002: 2: 647-56.
54. Kim C-H, Quarstein H, Bergseng E, Khosla C, Sollid LM. Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. Proc Nat Acad Sci U S A 2004: 101: 4175-9.
55. Jabri B, Sollid LM. Tissue-mediated control of immunopathology in coeliac disease. Nat Rev Immunol 2009: 9: 858-70.
56. Fallang LE, Bergseng E, Hotta K, Berg-Larsen A, Kim CY, Sollid LM. Differences in the risk of celiac disease associated with HLA-DQ2.5 or HLA-DQ2.2 are related to sustained gluten antigen presentation. Nat Immunol 2010: 10: 1096-101.
57. Vandiedonck C, Taylor MS, Lockstone HE et al. Pervasive haplotypic variation in the spliceo-transcriptome of the human major histocompatibility complex. Genome Res 2011: 21: 1042-54.
58. Klareskog L, Malmstrom V, Lundberg K, Padyukov L, Alfredsson L. Smoking, citrullination and genetic variability in the immunopathogenesis of rheumatoid arthritis. Sem Immunol 2011: 23: 92-8.
59. Wucherpfennig KW, Sethi D. T cell receptor recognition of self and foreign antigens in the induction of autoimmunity. Sem Immunol 2011: 23: 84-91.
60. Bharadwaj M, Illing P, Theodosis A, Purcell AW, Rossjohn J, McCluskey J. Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Ann Rev Pharm Tox 2011. In press.
61. Chessman D, Kostenko L, Lethborg T et al. Human leukocyte antigen class I-restricted activation of CD8+T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 2008: 28: 822-32.
62. Goulder PJR, Watkins DI. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat Rev Immunol 2008: 8: 619-30.
63. Depla E, van der Alta A, Livingston BD et al. Rational design of multiepitope vaccine encoding T-lymphocyte epitopes for treatment of chronic hepatitis B virus infections. J Virol 2008: 82: 435-50.
64. Dangoor A, Lorigan P, Keilholz U et al. Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunol Immunother 2010: 59: 863-73.
65. Sanchez-Mazas A, Fernandez-Vina M, Middleton D et al. Immunogenetics as a tool in anthropological studies. Immunology 2011: 133: 143-64.
66. Lie BA, Dupuy BM, Spurkland A et al. Molecular genetic studies of natives on Easter Island: evidence of an early European and Amerindian contribution to the Polynesian gene pool. Tissue Antigens 2007: 69: 10-8.
67. Thorsby E, Flam ST, Woldseth B et al. Further evidence of an Amerindian contribution to the Polynesian gene pool on Easter Island. Tissue Antigens 2009: 73: 582-5.
68. Thorsby E. The polynesian gene pool: an early contribution by Amerindians to Easter Island. Phil Trans R Soc B 2011. In press.
69. Lawler A. Beyond Kon-Tiki: did Polynesians sail to South America? Science 2010: 328: 1344-7.
70. Abi-Rached L, Jobin MJ, Kulkarni S et al. The shaping of modern human immune systems by multiregional admixture with archaic humans. Science 2011: 333. Published online 25 August 2011 (10-1126/science 1209202).
71. Green RE, Krause J, Briggs AW et al. A draft sequence of the Neandertal genome. Science 2010: 328: 710-22.
72. Reich D, Green RE, Kircher M et al. Genetic history of an archaic hominin group from Denisova cave in Siberia. Nature 2010: 468: 1053-60.